SABCS – Talk Bio

Pfizer’s Tukysa Shows Strong PFS Benefit in First-Line HER2+ Breast Cancer Maintenance at SABCS 2025, Sparking Debate with Enhertu

2 months ago talkbio0Tagged Enhertu, first-line maintenance, HER2-positive carcinoma of breast, HER2CLIMB-05, Pfizer, Progression-Free Survival, SABCS, Tukysa

Tukysa; Pfizer; HER2-positive breast cancer; SABCS 2025; HER2CLIMB-05; progression-free survival; Enhertu; first-line maintenance

NiKang Therapeutics Presents NKT5097: First-in-Class CDK2/4 Dual Degrader at SABCS 2025

2 months ago talkbio0Tagged Cancer Therapeutic Procedure, CDK2/4 degrader, Malignant neoplasm of breast, NiKang Therapeutics, SABCS

NiKang Therapeutics; NKT5097; CDK2/4 degrader; SABCS 2025; cancer therapy; breast cancer

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig in Advanced Triple-Negative Breast Cancer

2 months ago talkbio0Tagged Antibodies, Bispecific, BioNTech, BNT327, BREAST-01, disease control rate, Gene Expression, Myers Squibb, ORR, PD-L1, PD-L1xVEGF-A, Phase 2 trial, Progression-Free Survival, pumitamig, ROSETTA, SABCS, TNBC, Triple Negative Breast Neoplasms

BioNTech; Bristol Myers Squibb; pumitamig; BNT327; PD-L1xVEGF-A bispecific antibody; Phase 2 trial; triple-negative breast cancer; TNBC; confirmed ORR; disease control rate; progression-free survival; PD-L1 expression; ROSETTA BREAST-01; SABCS

Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Data in Leptomeningeal Metastases at SABCS 2025

2 months ago talkbio0Tagged central nervous system cancers, Dosage, Escalation, Metastatic Malignant Neoplasm to the Leptomeninges, Phase 1 (qualifier value), Plus Therapeutics, poster spotlight, ReSPECT-LM, REYOBIQ, SABCS, San Antonio Breast Cancer Symposium, Therapeutic radiology procedure

Plus Therapeutics; ReSPECT-LM; Phase 1; dose escalation; REYOBIQ; leptomeningeal metastases; San Antonio Breast Cancer Symposium; SABCS 2025; poster spotlight; central nervous system cancers; radiotherapeutics

Olema Oncology Unveils Promising Data for Oral SERD Palazestrant Ahead of Phase III Trials

1 year ago talkbio0Tagged Antonio Breast Cancer Symposium, ER-positive, HER2-negative, Malignant neoplasm of breast, NAA50 gene, Olema Oncology, Oral SERD, palazestrant, Phase 3 Clinical Trials, SABCS

Olema Oncology, palazestrant, oral SERD, Phase III trials, breast cancer, ER-positive, HER2-negative, San Antonio Breast Cancer Symposium (SABCS)